Related Experiment Videos
Cyclosporin A treatment for Diamond-Blackfan anemia
1Division of Pediatric Hematology/Oncology, Case Western Reserve University School of Medicine, Rainbow Babies and Childrens Hospital, Cleveland, Ohio.
Insights
Cyclosporin A offers temporary hematologic improvement in some Diamond-Blackfan anemia (DBA) patients, potentially reducing steroid dependence. However, benefits are transient, necessitating further research into its long-term efficacy and mechanisms for treating this rare blood disorder.
Area of Science:
- Hematology
- Immunology
- Pediatric Medicine
Background:
- Diamond-Blackfan anemia (DBA) is a rare red blood cell aplasia often treated with corticosteroids.
- Variable steroid response necessitates alternative therapies, such as transfusions, for some patients.
- Steroid therapy can lead to significant side effects, including growth failure and osteopenia.
Observation:
- Three patients with DBA were treated with cyclosporin A, an immunosuppressive agent.
- Two patients (DS, LS) experienced a significant hematocrit increase and reduced prednisone requirement with cyclosporin A.
- These benefits were transient, with hematocrit declining after 7-8 months, requiring increased prednisone and eventual transfusion support.
- One patient (RD) with steroid-refractory DBA showed no response to cyclosporin A.
- No cyclosporin A-associated toxicity was observed in any patient.
Findings:
- Cyclosporin A demonstrated a transient ability to improve hematologic parameters in some DBA patients.
- The drug allowed for a temporary reduction in corticosteroid dosage in two patients.
- Cyclosporin A was ineffective in a patient with steroid-refractory DBA.
Implications:
- Cyclosporin A may offer a short-term therapeutic option for select Diamond-Blackfan anemia patients.
- Further investigation is warranted to elucidate the mechanism of action of cyclosporin A in DBA.
- The potential clinical utility of cyclosporin A for steroid-unresponsive DBA requires additional study.
Abstract:
Diamond-Blackfan anemia (DBA) is characterized by a variable response to corticosteroid therapy. Patients poorly responsive to acceptable doses of steroid treatment require long-term transfusion therapy. We have treated three patients with DBA with the immunosuppressive agent cyclosporin A with limited success. Patients 1 (DS) and 2 (LS), half-siblings, were 13 and 9 years old, respectively, and remained transfusion independent for many years on steroid therapy. Both patients manifest steroid-associated growth failure and osteopenia, with resultant orthopedic complications. Oral cyclosporin therapy sufficient to achieve trough serum levels of 100-200 ng/ml was associated with a brisk 50-100% increase in hematocrit within 1 month of initiation of treatment and allowed for a gradual tapering of prednisone dose to approximately 20% of prior established maintenance dose. After 7-8 months, both patients developed progressive decline in hematocrit level requiring increased prednisone dose and, ultimately, transfusion support. Patient 3 (RD), a 5-year-old child with steroid refractory, transfusion-dependent DBA, was entirely unresponsive to cyclosporin therapy. No cyclosporin-associated toxicity occurred. Our observations indicated that cyclosporin A can transiently ameliorate the hematologic course of some patients with DBA. Further studies are in order to determine its mechanism of action and potential clinical utility in patients unresponsive to acceptable doses of steroid.